Product/Operations Update
Biocon Gets U.S. FDA Approval for Pebrilzo
Biocon received U.S. FDA approval for Pebrilzo, a pertuzumab biosimilar for HER2-positive breast cancer, with commercial launch expected in Q3 2028.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.



Pharmaceuticals & Biotechnology
Pharmaceuticals
58,995 Cr
Low Risk
173.4
39.0
1.2
1.7
447.00
318.50
Sales CAGR
Profit CAGR
ROE
ROCE

View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
3
Neutral
7
Bullish
4
Bearish
26
Neutral
7
Bullish
13
Bearish
23
Neutral
0
Bullish
9
Bearish
23
Neutral
0
Bullish
9
Bearish
23
Neutral
0
Bullish
9
Bearish
23
Neutral
0
Bullish
9
Biocon Ltd (BIOCON) is currently trading at 360.30 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Biocon Limited is an innovation-led, fully integrated biopharmaceutical company manufacturing biosimilars, insulin, generic medicines, complex APIs, and providing outsourced research services through Syngene. Its principal growth engine is global biosimilars, complemented by generics and Syngene’s contract research and development platform. Biocon Limited is transitioning from an investment-heavy phase toward commercial acceleration and operating leverage. Management expects a stronger second half of FY27, supported by new biosimilar launches, expanded insulin capacity, improving generics profitability, and a gradual recovery in Syngene’s services business. Biocon Limited’s Q2 FY27 reported performance was temporarily affected by logistics-related revenue deferrals equivalent to approximately 5% of quarterly revenue. Those shipments were recognized in October, meaning the company expects the associated revenue and incremental EBITDA contribution to appear in Q3 rather than being permanently lost. The $400 million, 10-year Brazilian Pertuzumab contract provides unusual revenue visibility for a biosimilar company, with supplies beginning in Q4 FY27 and the full annual run-rate expected from FY28. Separately, U.S. Yesintek market share reached 34%, reportedly surpassing the originator. Biocon Limited is strengthening its balance sheet while scaling operations: Q2 interest expense declined 12% year-on-year to INR 240 crores, whereas generics EBITDA increased to INR 64 crores from INR 7 crores. This combination suggests improving operating leverage, although Syngene remains in a transition year.
Over the past 52 weeks, Biocon Ltd has traded between a low of ₹318.50 and a high of ₹447.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Biocon Ltd has a market capitalization of approximately 58,994.93. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Biocon Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 173.36 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 58,994.93 Cr, Biocon Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Biocon Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Biocon Ltd is 173.36. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Biocon's Pebrilzo is FDA-approved for HER2-positive metastatic and early breast cancer in specified settings. In metastatic disease, it is used with trastuzumab and docetaxel, while early-breast-cancer treatment uses it with trastuzumab and chemotherapy.
Pebrilzo is Biocon's biosimilar to Perjeta. Its active ingredient is pertuzumab, and the source material identifies it as a solution for injection used in the context of HER2-positive breast cancer treatment.
Biocon has a licensed U.S. launch date for Pebrilzo in Q3 calendar 2028, subject to regulatory approvals. Management said the period before that date allows time for contracting and commercial preparation.
Biocon said certain biosimilar shipments were delayed and reached customers in October rather than before the September quarter-end. The company cited logistics challenges, including those related to the geopolitical situation, and said customer orders and product availability were already in place.
Product/Operations Update
Biocon received U.S. FDA approval for Pebrilzo, a pertuzumab biosimilar for HER2-positive breast cancer, with commercial launch expected in Q3 2028.
Regulatory/Compliance Filing
Biocon will meet analysts and institutional investors at conferences in Mumbai on November 17 and 18, 2026.
Earnings Call/Transcript
Biocon filed the transcript of its Q2 FY27 earnings call held on November 4, 2026, covering business updates, market expansion and financial performance.